Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo

We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified as BVRA in...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dijk, Remco, Aronson, Sem J., de Waart, Dirk R., van de Graaf, Stan F., Duijst, Suzanne, Seppen, Jurgen, Elferink, Ronald Oude, Beuers, Ulrich, Bosma, Piter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431759/
https://www.ncbi.nlm.nih.gov/pubmed/28490767
http://dx.doi.org/10.1038/s41598-017-01602-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431759/
https://www.ncbi.nlm.nih.gov/pubmed/28490767
http://dx.doi.org/10.1038/s41598-017-01602-w

Ejemplares similares